Overview

Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:
0

Participant gender:
All

Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investigators test the idea that the medication called "tiagabine" improves slow wave sleep and reduces OSA severity. The investigators will also test whether tiagabine raises the arousal threshold (more negative esophageal pressure), and whether detailed OSA "phenotyping" characteristics can predict the improvement in OSA severity with this intervention.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Brigham and Women's Hospital

Treatments:

Tiagabine

Criteria

Inclusion Criteria:

- Diagnosed OSA (moderate-to-severe; apnea hypopnea index >15 events/hr)

Exclusion Criteria:

- History of seizures